The procedure was conducted on a 49-year-old woman, the wife of an Armed Forces veteran, who had been waiting for a heart transplant for over two years. The HeartMate 3 LVAD, often referred to as ...

Pham, Chief Executive Officer, Cadrenal Therapeutics, Inc. “Together, we have a unique opportunity to evaluate tecarfarin in combination with the HeartMate 3(TM) LVAD, advancing our commitment ...

has performed India's first-ever Left Ventricular Assist Device (LVAD) implantation using the HeartMate 3 device in a ...

The HeartMate II is currently the only continuous-flow left-ventricular assist device (LVAD) approved by the FDA for both bridge-to-transplantation and destination therapy. Because of its ...

Abbott is the maker of the HeartMate 3™ LVAD, which is the only LVAD currently approved in the U.S. Having Abbott assist with many different facets of the Phase 3 TECH-LVAD trial is going to be ...

were randomly assigned in a 2:1 ratio to undergo implantation of a continuous-flow LVAD (HeartMate II ®) or a pulsatile-flow LVAD (HeartMate XVE ®). The mean age of enrolled patients was 62.5 ...

Another concern was whether end organ dysfunction or other comorbidities could be reduced or significantly improved with a period of VAD support. Of patients implanted with the Heartmate XVE ...

Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients Cadrenal Therapeutics ...

According to Dr. Dang Viet Duc, Deputy Director of the Cardiology Institute at 108 Military Central Hospital, the HeartMate 3 LVAD is among the most advanced cardiovascular technologies currently ...

Shuhaiber et al. compared post-transplant survival in a large cohort of patients who had pretransplant insertion of a first-generation, pulsatile, implantable LVAD (HeartMate ® XVE [Thoratec ...